WallStSmart

CareDx Inc (CDNA)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 4194% more annual revenue ($16.31B vs $379.81M). IQV leads profitability with a 8.3% profit margin vs -5.6%. IQV earns a higher WallStSmart Score of 72/100 (B).

CDNA

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CDNA.

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CDNA2 strengths · Avg: 8.0/10
Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

Areas to Watch

CDNA4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$882.07M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.3%2/10

ROE of -6.3% — below average capital efficiency

Profit MarginProfitability
-5.6%1/10

Currently unprofitable

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CDNA

The strongest argument for CDNA centers on Price/Book, Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : CDNA

The primary concerns for CDNA are EPS Growth, Market Cap, Return on Equity.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Key Dynamics to Monitor

CDNA profiles as a growth stock while IQV is a value play — different risk/reward profiles.

CDNA carries more volatility with a beta of 2.58 — expect wider price swings.

CDNA is growing revenue faster at 25.2% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (72/100 vs 36/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CareDx Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?